Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
Uveal melanoma is the most common primary intraocular malignant tumor in adults with 30% to 50% of patients that ultimately succumb to metastatic disease, mainly to the liver. (Shields et al. 1991) Although new diagnostic and therapeutic tools have been developed during the most recent years, only the eye conservation rate has been achieved, while the survival rate remains poor. The reason for this liver-homing is largely unknown, but it is conceivable that hepatic environmental factors may be implicated in the growth, dissemination, and progression of this malignancy. The insulin-like growth factor (IGF-1) that binds to the IGF-1 receptor (IGF-1R) is mainly produced in the liver. It has been shown to be crucial for tumor transformation, maintenance of malignant phenotype, promotion of cell growth, and prevention of apoptosis. (Baserga 1995) The hepatocyte growth factor/scatter factor (HGF/SF) is another growth factor produced in the liver and exerts its biological effects through binding to the plasma membrane receptor c-Met. The activation of this receptor by HGF/SF ligand can induce proliferation, motility, adhesion, and invasion of tumor cells. (Cruz et al. 2003) Metastasis is a process involving many components, including tumor cell adhesion, migration, extracellular matrix (ECM) proteolysis, and invasion. The tumor cells undergo intravasation, disperse via the vascular and the lymphatic systems, and finally extravasate to invade the secondary sites. In all these steps, proteolytic enzyme systems are involved, including the matrix metalloproteinase (MMP) system and the plasminogen activation system. The migration of a malignant cell through the ECM and the basement membrane requires proteolytic activities. (Stetler-Stevenson et al. 1993). Efforts to target the IGF-I system has been made with different types of cancer but not with uveal melanoma.
Economou
Mario-Alexander
MA
Cellular and Molecular Tumour Pathology, Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Sweden. mario-alexander.economou@sankterik.se
D000818:Animals; D015415:Biomarkers; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism*; D051379:Mice; D008967:Molecular Biology / Q000379:methods*; D011034:Podophyllotoxin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A; C415032:picropodophyllin; D017526:Receptor, IGF Type 1; D011034:Podophyllotoxin